Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

Journal of the American College of Cardiology - 22 Jun 2010

Epstein Robert S, Moyer Thomas P, Aubert Ronald E, O Kane Dennis J, Xia Fang, Verbrugge Robert R, Gage Brian F, Teagarden J Russell

Abstract excerpt

OBJECTIVES: This study was designed to determine whether genotype testing for patients initiating warfarin treatment will reduce the incidence of hospitalizations, including those due to bleeding or thromboembolism. BACKGROUND: Genotypic variations in CYP2C9 and VKORC1 have been shown to predict warfarin dosing, but no large-scale studies have prospectively evaluated the clinical effectiveness of genotyping in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Hemorrhage

Share to Hospitalization

Share to Thromboembolism

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 20381283
DOI: 10.1016/j.jacc.2010.03.009

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).PMID 20381283Read ↗

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.Semantic proximity Read ↗

A randomized trial of genotype-guided dosing of warfarin.Semantic proximity Read ↗

Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.Semantic proximity Read ↗

Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial.Semantic proximity Read ↗

Assessing Clinical Utility of Pharmacogenetic Testing in the Military Health SystemSemantic proximity Read ↗

Preliminary outcomes of preemptive warfarin pharmacogenetic testing at a large rural healthcare center.Semantic proximity Read ↗

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.Semantic proximity Read ↗

Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin.Semantic proximity Read ↗

Meta-Analysis of Genotype-Guided Versus Standard Dosing of Vitamin K Antagonists.Semantic proximity Read ↗

Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.Semantic proximity Read ↗

Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.Semantic proximity Read ↗

Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.